Posted by ABMN Staff on Mar 19th, 2024
HC Wainwright reissued their buy rating on shares of Century Therapeutics (NASDAQ:IPSC – Free Report) in a research report report published on Friday, Benzinga reports. They currently have a $13.00 price target on the stock.
Separately,...
More of this article »